Valuation : Regenicin Inc

Market Cap 76.74K 66.19K 62.28K 56.77K 107K 7.29M 107K 738K 287K 3.7M 288K 282K 12.29M P/E 2021
-2x
P/E 2022 -0.71x
Enterprise Value 704K 607K 571K 521K 978K 66.85M 985K 6.77M 2.63M 33.99M 2.64M 2.59M 113M EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
96.65%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 76 23/01/2011
Director of Finance/CFO 76 12/09/2010
Chief Operating Officer - 31/08/2022
Director TitleAgeSince
Director/Board Member 76 12/09/2010
Chairman 76 14/07/2010
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+2.55%+46.72%+90.66% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.99%-10.72%+455.09% 26.6B
+0.33%-9.64%+1.95%-15.70% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+4.29%+52.03%+154.09% 13.54B
Average +0.01%-3.84%+50.70%+184.26% 30.67B
Weighted average by Cap. +0.15%-2.87%+47.00%+145.57%

Financials

2021 2022
Net sales - -
Net income -877K -756K -712K -649K -1.22M -83.27M -1.23M -8.43M -3.28M -42.34M -3.29M -3.22M -140M -639K -551K -519K -473K -888K -60.69M -895K -6.15M -2.39M -30.86M -2.4M -2.35M -102M
Net Debt 598K 516K 486K 443K 831K 56.8M 837K 5.75M 2.23M 28.88M 2.25M 2.2M 95.82M 627K 541K 509K 464K 871K 59.57M 878K 6.03M 2.34M 30.28M 2.36M 2.3M 100M
Logo Regenicin Inc
Regenicin, Inc. is a biotechnology company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. Its second product is TempaDerm. TempaDerm uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients, such as ulcers.
Employees
-